Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Sponsor
Roswell Park Cancer Institute
Study ID
NCT00524069
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • capecitabine — DRUG
  • gemcitabine hydrochloride — DRUG
  • flow cytometry — OTHER
  • laboratory biomarker analysis — OTHER
  • adjuvant therapy — PROCEDURE
  • computed tomography — PROCEDURE
  • neoadjuvant therapy — PROCEDURE

Study Details

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving gemcitabine and capecitabine together with bevacizumab may kill more tumor cells. PURPOSE: This clinical trial is studying the side effects and how well giving gemcitabine and capecitabine together with bevacizumab works in treating patients with pancreatic cancer that can be removed by surgery.

Key Dates

First listed
Sep 3, 2007
Start date
Jan 31, 2007
Status verified
Jan 2013
Primary completion
Nov 30, 2007

Study Design

Enrollment
0 participants (actual)
Primary purpose
TREATMENT

Primary Outcome Measure

Feasibility and safety

Related Studies